Status:

COMPLETED

Auricular Vagus Nerve Stimulation in Painful and Inflammatory Erosive Hand Osteoarthritis

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborating Sponsors:

Schwa medico (device lending)

Conditions:

Osteoarthritis

Musculoskeletal Pain

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

Erosive hand osteoarthritis (EHOA) is a difficult-to-treat subtype of HOA characterized by local and systemic low-grade inflammation as well as by high level of pain and of disability. Auricular tran...

Detailed Description

Symptomatic hand osteoarthritis (HOA) affects 8-16% of the general population above 50 years and involves interphalangeal (IP) joints. HOA symptoms include pain, stiffness and are responsible for disa...

Eligibility Criteria

Inclusion

  • Age ≥ 18 years
  • Symptomatic HOA according to the American College of Rheumatology criteria
  • Erosive HOA according to hand radiographs performed in routine practice showing ≥1 erosive digital joint based on Verbruggen-Veys scoring definition
  • Hand pain level ≥ 40/100 mm on VAS at inclusion at least half of days of the 30 last days
  • At least ≥1 symptomatic IP joint with clinical soft swelling or erythema at inclusion
  • reported inadequate response or adverse effects or contraindication with existing medication (including acetaminophen, oral NSAIDs)
  • Informed written consent
  • Patient affiliated to a social security scheme NB: Clinical inflammation, ultrasound abnormalities and radiographic erosions have not have to be present in the same joint.

Exclusion

  • Isolated thumb-base OA (i.e., rhizarthrosis)
  • Predominance of the pain in the thumb base rather than digital pain
  • Other inflammatory joint disease (e.g. gout, reactive arthritis, rheumatoid arthritis, psoriatic arthritis, Lyme disease)
  • Psoriasis
  • Current skin disease of the left ear (e.g., eczema, urticarial lesion, skin infection, external otitis)
  • Ear canal not adapted to apply the auricular electrode
  • Known history of cardiac rhythm disturbances, atrio-ventricular block \> first degree, or total bundle branch block
  • Symptomatic orthostatic hypotension or repeated vasovagal syncope history
  • History of vagotomy
  • Severe Asthma
  • Treated sleep apnea
  • Existence of a pain syndrome of the upper limbs, which would interfere with the monitoring of pain
  • Fibromyalgia
  • Use of other electrically active medical devices (e.g. pacemaker, TENS for chronic pain)
  • Use of oral, intramuscular or intra-articular or intravenous steroids, other anti-synovial agents (e.g. slow-acting anti-rheumatic drugs such as methotrexate, sulfasalazine), intra-articular hyaluronic acid to the hand joints within the last 3 months
  • Any new hand OA treatment in the previous 2 months, including physiotherapy and provision of new hand splint.
  • Planned hand surgery in the next 3 months.
  • Use of any investigational (unlicensed) drug within 3 months prior to screening.
  • Evidence of serious uncontrolled concomitant medical condition, including cardiovascular, nervous system, pulmonary, renal, hepatic, endocrine, gastro-intestinal disease or epilepsy, which in the opinion of the investigator makes them unsuitable for the study
  • Pregnant or breastfeeding woman
  • Patient under legal protection measure (tutorship or curatorship) and patient deprived of freedom
  • Use of VNS before the study
  • Use of NSAIDs or paracetamol less than 48h before the D0 visit

Key Trial Info

Start Date :

April 8 2021

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 30 2022

Estimated Enrollment :

148 Patients enrolled

Trial Details

Trial ID

NCT04520516

Start Date

April 8 2021

End Date

June 30 2022

Last Update

September 16 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Service de Rhumatologie - Hôpital Saint Antoine

Paris, France, 75012